Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib ; day:12 ; month:12 ; year:2018 ; pages:1-9
Targeted oncology ; (12.12.2018), 1-9
- Urheber
-
Hochmair, Maximilian J.
Buder, Anna
Schwab, Sophia
Burghuber, Otto C.
Prosch, Helmut
Hilbe, Wolfgang
Cseh, Agnieszka
Fritz, Richard
Filipits, Martin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-018-0612-z
- URN
-
urn:nbn:de:101:1-2019012819070039355838
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hochmair, Maximilian J.
- Buder, Anna
- Schwab, Sophia
- Burghuber, Otto C.
- Prosch, Helmut
- Hilbe, Wolfgang
- Cseh, Agnieszka
- Fritz, Richard
- Filipits, Martin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Erfolgreiche Behandlung eines Afatinib-refraktären nicht kleinzelligen Bronchialkarzinoms mit seltenen komplexen EGFR-Mutationen mit Pembrolizumab: ein Fallbericht
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Erfolgreiche Behandlung eines Afatinib-refraktären nicht kleinzelligen Bronchialkarzinoms mit seltenen komplexen EGFR-Mutationen mit Pembrolizumab: ein Fallbericht
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients